Author: Customer Service

The share repurchase programme runs as from 26 February 2025 and up to and including 30 January 2026 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 2.25 billion, cf. Corporate Announcement No. 3/2025 of 26 February 2025. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called “Market Abuse Regulation”, and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 12,000 581.70 6,980,4253 March 2025 4,000 583.42 2,333,6724 March 2025 3,888 568.21 2,209,2075...

Company announcement no. 11 / 2025Schindellegi, Switzerland – 10 March 2025 Trifork Group: Weekly report on share buyback On 28 Februay 2025, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 4 March 2025 up to and including no later than 30 June 2025. The buyback program will not be active from 9 to 15 April 2025. For details, please see company announcement no. 7 of 28 February 2025. Under the share buyback program, Trifork will purchase shares for up to a total of DKK 14.92 million (approximately EUR 2 million). Prior to the launch of the share buyback, Trifork held 256,329 treasury shares, corresponding to 1.3% of the share...

VANCOUVER, British Columbia, March 09, 2025 (GLOBE NEWSWIRE) — Methanex Corporation (TSX:MX) (Nasdaq:MEOH) announced today that its 1.8 million tonne methanol plant, Geismar 3 (G3), in Geismar, Louisiana was impacted by an unplanned outage in late February. Upon completing various inspections, management has decided to complete repairs to the autothermal reformer (ATR), and management currently estimates a plant startup by early May 2025. During this outage, management is taking the opportunity to bring forward the completion of other planned maintenance work on G3 which was part of a previously budgeted three-week outage which is no longer expected to be required. This outage is expected to primarily impact the second quarter financial results due to lower produced methanol sales. The cost of these repairs is not expected to be...

SINGAPORE, March 09, 2025 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Zarif Munir as a Senior Managing Director and Head of Southeast Asia Business Transformation and Enqing Wang as a Managing Director in the firm’s Business Transformation practice within the Corporate Finance & Restructuring segment. Luke Schaeffer, Global Leader of Strategy and Transformation at FTI Consulting, said, “We are delighted to welcome Zarif and Enqing to our growing Business Transformation practice in Asia. Their expertise in business transformation, portfolio management and operational improvement will enable us to address critical challenges such as driving efficiency, unlocking growth opportunities and navigating complex market dynamics. Investing in these capabilities is essential as businesses in...

A loan agreement has been signed between Reykjavík Energy and the Council of Europe Development Bank (CEB), as announced to the stock exchange on September 30, 2024, following the bank’s approval.The loan amount is EUR 75 million and will be used to develop heating and water utilities, including enhancing the resilience of utility systems against natural hazards. Contact:Snorri Hafsteinn Þorkelsson CFO snorri.hafsteinn.thorkelsson@orkuveitan.is

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placebo Data support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under review in the U.S. and the European Union TARRYTOWN, N.Y. and PARIS, March 08, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent® (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP). The data were shared...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AADFive times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placeboData support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under review in the US and the EUParis and Tarrytown, NY, March 8, 2025. Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a late-breaking oral presentation...

The Board of Directors of Kaldalón hf. hereby announces that the Annual General Meeting of the company will be held on Wednesday, April 3, 2025, at 16:00 GMT. The meeting will be held at Reykjavík Natura, Nauthólsvegur 52, 101 Reykjavík. Enclosed is the agenda for the Annual General Meeting.  Meeting documents and further information concerning the meeting is available on the website kaldalon.is/adalfundur2025.  

ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and systemic lupus Phase 2 OLE data of ESK-001 at 40 mg BID demonstrated sustained or increasing clinical responses through week 52 on PASI 90, PASI 100, and sPGA 0 ESK-001 was generally well-tolerated at one year, with no new safety findings Data further support ESK-001’s potential to offer a highly differentiated and best-in-class treatment option for people with moderate-to-severe plaque psoriasis Phase 3 ONWARD program ongoing with topline data expected in Q1 2026SOUTH SAN FRANCISCO, Calif., March 08, 2025 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes...

For Immediate Release – Not for Dissemination in the United States or through U.S. Newswire Services Greenville, South Carolina, March 07, 2025 (GLOBE NEWSWIRE) — ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) is pleased to announce that it has closed its previously announced non-brokered private placement (the “Offering”) for gross proceeds of C$800,000, through the sale of 10,000,0000 units of the Company (the “Units”) at a price of C$0.08 per Unit. Each Unit consists of one class A subordinate voting share in the capital of the Company (a “Share”) and one Share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase an additional Share at a price of C$0.12 for 24 months from issuance, provided that if at any time after the closing date the daily volume weighted average trading price of the...